Novel anti-inflammatory drugs in hypertension

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 859-864

  Hermann, Matthias ^a   Ruschitzka, Frank ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cardiovascular risk; Coxib; Cyclooxygenase; Hypertension; Inflammation; NSAID

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CANNABINOID RECEPTOR ANTAGONIST; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOSARTAN; MONOCYTE CHEMOTACTIC PROTEIN 1; NAPROXEN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLMESARTAN; PIOGLITAZONE; PRAVASTATIN; PROSTAGLANDIN SYNTHASE INHIBITOR; RIMONABANT; ROFECOXIB; ROSIGLITAZONE; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ADENOMA; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG MEGADOSE; DRUG POTENTIATION; EDITORIAL; ESSENTIAL HYPERTENSION; HEART FAILURE; HUMAN; HYPERTENSION; INFLAMMATION; META ANALYSIS; NONHUMAN; OSTEOARTHRITIS; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; HUMANS; HYPERTENSION;

EID: 33645280050     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfk054     Document Type: Editorial

References (77)

1. Liuzzo G, Biasucci LM, Gallimore JR et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994; 331: 417-424
2. Ridker PM, Hennekens CH, Buring JE et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843
3. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002; 347: 1557-1565
4. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107: 499-511
5. Khera A, McGuire DK, Murphy SA et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol 2005; 46: 464-469
6. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397
7. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000; 102: 2165-2168
8. Pasceri V, Cheng JS, Willerson JT et al. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534
9. Wang CH, Li SH, Weisel RD et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003; 107: 1783-1790
10. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis. Circulation 2001; 103: 1194-1197
11. Venugopal SK, Devaraj S, Yuhanna I et al. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002; 106: 1439-1441
12. Verma S, Wang CH, Li SH et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002; 106: 913-919
13. Teragawa H, Fukuda Y, Matsuda K et al. Relation between C-reactive protein concentrations and coronary microvascular endothelial function. Heart 2004; 90: 750-754
14. Fichtlscherer S, Rosenberger G, Walter DH et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102: 1000-1006
15. Fichtlscherer S, Zeiher AM. Endothelial dysfunction in acute coronary syndromes: Association with elevated C-reactive protein levels. Ann Med 2000; 32: 515-518
16. Sternik L, Samee S, Schaff HV et al. C-reactive protein relaxes human vessels in vitro. Arterioscler Thromb Vasc Biol 2002; 22: 1865-1868
17. Devaraj S, Du Clos TW, Jialal I. Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol 2005; 25: 1359-1363
18. Schwedler SB, Amann K, Wernicke K et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 2005; 112: 1016-1023
19. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906
20. Hingorani AD, Cross J, Kharbanda RK et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102: 994-999
21. Mutru O, Laakso M, Isomaki H et al. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology 1989; 76: 71-77
22. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126
23. Pasceri V, Yeh ET. A tale of two diseases: Atherosclerosis and rheumatoid arthritis. Circulation 1999; 100: 2124-2126
24. van der Wal AC, Becker AE, van der Loos CM et al. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44
25. Hurlimann D, Forster A, Noll G et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002; 106: 2184-2187
26. Kharbanda RK, Walton B, Allen M et al. Prevention of inflammation-induced endothelial dysfunction: A novel vasculo-protective action of aspirin. Circulation 2002; 105: 2600-2604
27. Blake GJ, Rifai N, Buring JE et al. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993-2999
28. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844.
29. Sesso HD, Buring JE, Rifai N et al. C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945-2951.
30. Engstrom G, Janzon L, Berglund G et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol 2002; 22: 2054-2058
31. Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336: 973-979
32. Schillaci G, Pirro M, Gemelli F et al. Increased C-reactive protein concentrations in never-treated hypertension: The role of systolic and pulse pressures. J Hypertens 2003; 21: 1841-1846.
33. Dodson PM, Shine B. Retinal vein occlusion: C-reactive protein and arterial hypertension. Acta Ophthalmol (Copenh) 1984; 62: 123-130
34. Bautista LE, Lopez-Jaramillo P, Vera LM et al. Is C-reactive protein an independent risk factor for essential hypertension? J Hypertens 2001; 19: 857-861
35. Choi H, Cho DH, Shin HH et al. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J 2004; 68: 297-303
36. Curb JD, Abbott RD, Rodriguez BL et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003; 107: 2016-2020
37. Cao JJ, Thach C, Manolio TA et al. C-reactive protein, carotid intima-media thickness, and incidence of ischemic stroke in the elderly: the Cardiovascular Health Study. Circulation 2003; 108: 166-170
38. Mahmud A, Feely J. Arterial stiffness is related to systemic inflammation in essential hypertension. Hypertension 2005; 46(5): 1118-1222
39. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528
40. Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102
41. Solomon SD, McMurray JJ, Pfeffer MA et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080
42. Chenevard R, Hurlimann D, Bechir M et al. Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 2003; 107: 405-409
43. Widlansky ME, Price DT, Gokce N et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42: 310-315
44. Hermann M, Camici G, Fratton A et al. Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003; 108: 2308-2311
45. Hermann M, Shaw S, Kiss E et al. Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005; 45: 193-197
46. Steffel J, Hermann M, Greutert H et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005; 111: 1685-1689
47. Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959-963
48. White WB, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39: 929-934
49. Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005; 165: 161-168
50. Aw TJ, Haas SJ, Liew D et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165: 490-496
51. Rossat J, Maillard M, Nussberger J et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999; 66: 76-84
52. Catella-Lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289: 735-741
53. Feenstra J, Heerdink ER, Grobbee DE et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: The Rotterdam Study. Arch Intern Med 2002; 162: 265-270
54. Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: A population-based cohort study. Lancet 2004; 363: 1751-1756
55. Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxygenase-2-specific inhibitors. Am J Med 2001; 110 [Suppl 3A]; 33S-42S
56. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289-300
57. Yamanari H, Nakamura K, Kakishita M et al. Effects of cyclooxygenase inhibition on endothelial function in hypertensive patients treated with angiotensin-converting enzyme inhibitors. Clin Cardiol 2004; 27: 523-527
58. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355: 253-259
59. Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153
60. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-788
61. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103-1107
62. Kranzhofer R, Schmidt J, Pfeiffer CA et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1999; 19: 1623-1629
63. Skurk T, van Harmelen V, Hauner H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. Arterioscler Thromb Vasc Biol 2004; 24: 1199-1203
64. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
65. Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998; 98: 839-844
66. Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352: 20-28
67. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulation 2003; 108: 2292-2297
68. Ogata T, Miyauchi T, Sakai S et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-1488
69. Diep QN, Benkirane K, Amiri F et al. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol 2004; 36: 295-304
70. Diep QN, El Mabrouk M, Cohn JS et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: Role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-2302
71. Pfutzner A, Marx N, Lubben G et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: Results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931
72. Van Gaal LF, Rissanen AM, Scheen AJ et al. Effects of the cannabinoid-I receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1389-1397
73. Batkai S, Pacher P, Osei-Hyiaman D et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 2004; 110: 1996-2002
74. Croci T, Landi M, Galzin AM et al. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 2003; 140: 115-122
75. Massa F, Marsicano G, Hermann H et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004; 113: 1202-1209
76. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler Thromb Vasc Biol 2005; 25(6): 1225-1230
77. Clapp BR, Hirschfield GM, Storry C et al. Inflammation and endothelial function: Direct vascular effects of human C-reactive protein on nitric oxide bioavailability. Circulation 2005; 111(12): 1530-1536